There’s a good article recently published on the Stanford University Medicine website on the revolution going on in the development of cancer cures and the part adaptive trial designs can play in it. Read more
...moreScott Berry demonstrates the use of the Bayesian Augmented Control feature in FACTS via a worked example. Scott is joined by Martin Kimber after the presentation to answer questions on using FACTS and other trial related topics. Click here to register for the on demand webinar.
...moreThe randomized controlled trial has taken medical research to a high scientific plateau. But it is more than 60 years old and had changed very little over that period. We cannot be satisfied with the status quo. Read more from Don’s interview with the ASCO post at: http://www.ascopost.com
...moreIt is good to see recommendations for the FDA to be funded so they can better review and help foster adaptive clinical trials…read more
...moreThe ADAPT Personalized Medicine Congress will be September 7 – 9 and will be held in Philadelphia. I’m happy to say that Tessella, and our partners the Berry Consultants, will be attending. Last year, the event attracted a great crowd from across the industry, so I’m looking forward to this year. I’ll be giving a [...]
...moreI was part of the Tessella team present at the SAS stand at the recent DIA annual meeting in Chicago. SAS were kind enough to host us as part of an ongoing initiative focusing on optimizing clinical research (see http://www.sas.com/news/preleases/hlsconf-clinicaltrials.html). At DIA I was struck by the number of CROs putting forward their adaptive trial [...]
...moreAdoption of adaptive designs in clinical trials has been particularly slow in oncology, in part because clinical endpoints in cancer tend to be long-term, and this means that few patients will experience an endpoint in the early stages of a trial and so be able to help direct its course. Click here to read how the [...]
...moreFocus group and survey confirm growing complexity of drug development and increasing adoption of smarter clinical trials Tom Parke, Head of Clinical Technologies, Tessella I was lucky enough to join a focus group at the recent 8th Annual SAS Health Care & Life Sciences Executive Conference (http://www.sas.com/news/preleases/hlsconf-clinicaltrials.html). The group comprising of selected pharmaceutical industry executives, [...]
...moreWhat’s Wrong with Phase II Trials? Genetic Engineering News Dr. Miller noted that the use of adaptive designs “should go a long way in increasing the likelihood of a successful early-phase clinical trial. … http://www.genengnews.com/analysis-and-insight/what-s-wrong-with-phase-ii-trials/77899364/
...moreAdaptive designs for clinical trials are being used increasingly in many areas of medical research. An adaptive design differs from a traditional design in … http://jco.ascopubs.org/content/29/6/606.full
...more© Copyright 2012 Tessella plc | Sitemap
